Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013007563 - FUSION PROTEINS RELEASING RELAXIN AND USES THEREOF

Publication Number WO/2013/007563
Publication Date 17.01.2013
International Application No. PCT/EP2012/062956
International Filing Date 04.07.2012
IPC
C07K 14/64 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
64Relaxins
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/643
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
A61K 47/644
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
644Transferrin, e.g. a lactoferrin or ovotransferrin
A61K 47/6811
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6811the drug being a protein or peptide, e.g. transferrin or bleomycin
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
Applicants
  • BAYER INTELLECTUAL PROPERTY GMBH [DE]/[DE] (AllExceptUS)
  • HAUPTS, Ulrich [DE]/[DE] (UsOnly)
  • WILMEN, Andreas [DE]/[DE] (UsOnly)
Inventors
  • HAUPTS, Ulrich
  • WILMEN, Andreas
Common Representative
  • BAYER INTELLECTUAL PROPERTY GMBH
Priority Data
11173328.308.07.2011EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FUSION PROTEINS RELEASING RELAXIN AND USES THEREOF
(FR) PROTÉINES DE FUSION LIBÉRANT DE LA RELAXINE ET LEURS UTILISATIONS
Abstract
(EN)
The present invention provides Relaxin fusion proteins, wherein a linker connects the carboxy-terminus of Relaxin with a proteinaceous half-life extending moiety and the linker comprises a protease cleavage site. Therefore, the invention provides Relaxin fusion polypeptides with extended half-life whereby the fusion protein by itself serves as a depot for release of the biologically active Relaxin. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, cells expressing the Relaxin fusion polypeptides, pharmaceutical compositions and medical use of such fusion polypeptides.
(FR)
Cette invention concerne des protéines de fusion à base de relaxine comprenant un lieur qui relie l'extrémité carboxy-terminale de la relaxine à un fragment prolongeant la demi-vie de la protéine, le lieur comprenant un site de clivage protéasique. Par conséquent, cette invention concerne des polypeptides de fusion à base de relaxine ayant une demi-vie prolongée, ladite protéine de fusion servant en soi de dépôt pur la libération d'une relaxine biologiquement active. Des séquences d'acides nucléiques codant pour les polypeptides de fusion précités, des vecteurs les contenant, des cellules exprimant lesdits polypeptides de fusion à base de relaxine, des compositions pharmaceutiques et l'utilisation médicale de ces polypeptides de fusion sont en outre décrits.
Latest bibliographic data on file with the International Bureau